Shield Therapeutics   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Weybridge United Kingdom (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2011
NCT01340872
First Marketed Drug
2019
ferric maltol (Accrufer)
First NDA Approval
2019
ferric maltol (Accrufer)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Phosphate Therapeutics | Shield Therapeutics | SHIELD TX